The following was taken from .......

The following was taken from .... www.thetradercentral.com/news



Prima Biomed

Prima Biomed is an Australian biotech specialising in cancer treatment. The company focuses on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. The new technology involves stimulating the patients immune system to attack the malignant tumour cells that are responsible for the disease. Stimulation of the patient's immune system can be achieved by two different methods; injecting a cancer vaccine which trains the immune system to recognise tumour cells and eliminate them from the body. The second method involves the administration of therapeutic antibodies, which recruits the immune system to destroy the tumour cells.

Cvac immunothearpy has been designed as a treatment for Ovarian Cancer. The Cancer is an ever increasing concern for Australian women, According to the Ovarian Cancer council More than 1200 women are diagnosed with ovarian cancer in Australia each year and 800 women will die from the disease. Current treatment for Ovarian Cancer includes surgery, chemotherapy and radio therapy, these treatments are both expensive and can have significant side-effects for patients. Cvac offers patients a friendly alternative to these treatments which could potentially change the way the cancer is treated in the future. US based biotech Dendreon have already had great success with a their own cellular immunotherapy treatment ; Provenge. Dendreon's success is a breakthrough in immunotherapy technology and provides some validation for Prima and their aspirations for Cvac



And also this...


Prima Biomed continues to record significantly large volumes of trade, below are the Volumes since the start of the month.

April 1- 27,083,998
April 4- 27,083,998
April 5- 18,568,155
April 6- 39,870,705
April 7- 41,819,320
April 8- 61,366,857
April 11- 55,059,099
April 12- 35,763,077
April 13- 18,157,025

The large volume represents strong demand for the stock and accumulation amongst traders and investors. It is likely heavy institution buying is taking place with trading houses trying to build a stake in Prima before the next leg up. With the increasing popularity of biotech stocks , PRR looks set to be the next stock to go on a significant run.

Since the beginning of April Prima have gained 12% (8c), with a share price at close of 38c. Prima aim to be listed on the NASDAQ in the coming months allowing American institutions and investors to acquire shares in the company. Prima have every chance of being a big hit on the NASDAQ, Dendreon who also specialise in the treatment of cancer vaccinations have performed extremely well over the last year.